Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.

Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.

Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-5N-(methyl-d3)pyridazine-3-carboxamide of the formula: Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Abstract: The present application provides processes for preparing 4-[3-(cyanomethyl)-3-(3?,5?-dimethyl-1H, 1?H-4,4?-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, and phosphoric acid salt thereof, which is useful as a selective (Janus kinase 1) JAK1 inhibitor, as well as salt forms and intermediates related thereto.

Abstract: Disclosed is a process for preparing Compound 8: comprising the step of reacting Compound of 7: wherein R is C1-8 alkyl or benzyl in the presence of a base. Also disclosed are intermediates and processes for preparing the intermediates.

Abstract: The present application provides processes for preparing 4-[3-(cyanomethyl)-3-(3?,5?-dimethyl-1H, 1?H-4,4?-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, and phosphoric acid salt thereof, which is useful as a selective (Janus kinase 1) JAK1 inhibitor, as well as salt forms and intermediates related thereto.

Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.

Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Abstract: Disclosed is a process for preparing Compound 8: comprising the step of reacting Compound of 7: wherein R is C1-8 alkyl or benzyl in the presence of a base. Also disclosed are intermediates and processes for preparing the intermediates.

Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Abstract: Disclosed is a process for preparing Compound 8: (8) comprising the step of reacting Compound of 7: (7) wherein R is C1-8 alkyl or benzyl in the presence of a base. Also disclosed are intermediates and processes for preparing the intermediates.

Abstract: The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

Abstract: Disclosed is a process for preparing Compound 8: (8) comprising the step of reacting Compound of 7: (7) wherein R is C1-8 alkyl or benzyl in the presence of a base. Also disclosed are intermediates and processes for preparing the intermediates.

Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.

Abstract: The present application provides processes for preparing (R)-4-(3-((S)-1-(4-amino-3-methyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one, which is useful as an inhibitor phosphoinositide 3-kinase-delta (PI3K?), as well as a salt form and intermediates related thereto.

Abstract: Techniques are generally described related to a method and system for treating an injury with a bone screw. One example bone screw may be configured to fracture at a pre-selected frangible location so that the point of failure is not in an inaccessible location, e.g., deeply embedded below the surface of a treated bone. The bone screw may further include a material disposed over the frangible location that is designed to temporarily strengthen the screw and selected to be absorbed by the body over a period of time after installation of the screw in the bone. One example bone screw may include an unthreaded portion that is configured to facilitate removal of an embedded screw fragment from a bone in the event that the screw fails in vivo.

Abstract: A rod system includes two rods each with a head and a shaft, two elastic members each fitted around one shaft against one head, and a case defining a first inner portion, a second inner portion, and a third inner portion in communication with the first and the second inner portions. A first rod with a first elastic member is seated in the first inner portion so the first elastic member abuts the bottom of first inner portion and the first head protrudes into the third inner portion. A second rod and a second elastic member is seated in the second portion so the second elastic member abuts the bottom of the second inner portion and the second head protrudes into the third inner portion and abuts the first head.

Abstract: Techniques are generally described related to a method and system for treating an injury with a bone screw. One example bone screw may be configured to fracture at a pre-selected frangible location so that the point of failure is not in an inaccessible location, e.g., deeply embedded below the surface of a treated bone. The bone screw may further include a material disposed over the frangible location that is designed to temporarily strengthen the screw and selected to be absorbed by the body over a period of time after installation of the screw in the bone. One example bone screw may include an unthreaded portion that is configured to facilitate removal of an embedded screw fragment from a bone in the event that the screw fails in vivo.

Abstract: A rod system includes two rods each with a head and a shaft, two elastic members each fitted around one shaft against one head, and a case defining a first inner portion, a second inner portion, and a third inner portion in communication with the first and the second inner portions. A first rod with a first elastic member is seated in the first inner portion so the first elastic member abuts the bottom of first inner portion and the first head protrudes into the third inner portion. A second rod and a second elastic member is seated in the second portion so the second elastic member abuts the bottom of the second inner portion and the second head protrudes into the third inner portion and abuts the first head.

Abstract: Techniques are generally described related to a method and system for treating an injury with a bone screw. One example bone screw may be configured to fracture at a pre-selected frangible location so that the point of failure is not in an inaccessible location, e.g., deeply embedded below the surface of a treated bone. The bone screw may further include a material disposed over the frangible location that is designed to temporarily strengthen the screw and selected to be absorbed by the body over a period of time after installation of the screw in the bone. One example bone screw may include an unthreaded portion that is configured to facilitate removal of an embedded screw fragment from a bone in the event that the screw fails in vivo.